Ofatumumab for Multiple Sclerosis Does Not Increase COVID-19 Severity

No increased risk for breakthrough COVID-19 infection, severe COVID-19, or fatal outcomes among patients receiving ofatumumab for relapsing multiple sclerosis (MS) was found in an updated analysis presented at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) held from June 1-4, in National Harbor, Maryland. SARS-CoV-2 is associated with a severe respiratory infection which can be fatal. Since the beginning of the pandemic, there has been concern and uncertainty about specific risks for patients receiving disease-modifying therapy (DMT).